Efficiency vs equality: Health reform in Canada - Stingl,M, Wilson,D

被引:0
|
作者
Sherwood, JJ
机构
关键词
D O I
10.1177/019394599701900310
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
引用
收藏
页码:401 / 404
页数:4
相关论文
共 9 条
  • [1] Efficiency vs. equality: Health reform in Canada - Stingl,M, Wilson,D
    Thorne, S
    [J]. CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 1997, 88 (03): : 212 - 212
  • [2] Efficiency vs. equality: Health reform in Canada
    McArthur, WJ
    [J]. CANADIAN PUBLIC POLICY-ANALYSE DE POLITIQUES, 1998, 24 (04): : 534 - 534
  • [3] Efficiency and equality: Health reform in Canada.
    Meredith, G
    [J]. CANADIAN JOURNAL ON AGING-REVUE CANADIENNE DU VIEILLISSEMENT, 1998, 17 (01): : 110 - 113
  • [5] THE RIGHT MEDICINE - HOW TO MAKE HEALTH REFORM WORK TODAY - DUNDIFF,D, MCCARTHY,M
    ALTENSTETTER, C
    [J]. HEALTH POLICY, 1995, 33 (01) : 68 - 70
  • [6] Canada's century: Governance in a maturing society - Essays in honour of John Meisel - Franks,CES, Hodgetts,JE, Dwivedi,OP, Williams,D, Wilson,VS
    Smith, J
    [J]. CANADIAN JOURNAL OF POLITICAL SCIENCE-REVUE CANADIENNE DE SCIENCE POLITIQUE, 1996, 29 (01): : 151 - 151
  • [7] Canada's century governance in a maturing society - Essays in honour of John Meisel - Franks,CES, Hodgetts,JE, Dwivedi,OP, Williams,D, Wilson,VS
    Lachapelle, G
    [J]. CANADIAN PUBLIC POLICY-ANALYSE DE POLITIQUES, 1997, 23 (01): : 87 - 91
  • [8] Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 (C20) vs 25mg/m2 (C25) in post-docetaxel (D) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Eisenberger, M.
    Hardy-Bessard, A-C.
    Kim, C. S.
    Geczi, L.
    Ford, D.
    Mourey, L.
    Carles, J.
    Parente, P.
    Font, A.
    Kacso, G.
    Barnes, G.
    Wang, H.
    Zhang, W.
    Ozatilgan, A.
    de Bono, J.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [9] PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    de Bono, J. S.
    Hardy-Bessard, A-C.
    Kim, C. S.
    Geczi, L.
    Ford, D.
    Mourey, L.
    Carles, J.
    Parente, P.
    Font, A.
    Kacso, G.
    Chadjaa, M.
    Zhang, W.
    Bernard, J.
    Eisenberger, M.
    [J]. ANNALS OF ONCOLOGY, 2016, 27